| CTRI Number |
CTRI/2023/06/053608 [Registered on: 07/06/2023] Trial Registered Prospectively |
| Last Modified On: |
08/11/2023 |
| Post Graduate Thesis |
No |
| Type of Trial |
Interventional |
|
Type of Study
|
Other (Specify) [Cosmeceuitcal ] |
| Study Design |
Single Arm Study |
|
Public Title of Study
|
Safety assessment of cosmetic product |
|
Scientific Title of Study
|
Evaluation of irritation potential of skin care formulation on healthy human subjects. |
| Trial Acronym |
|
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| D01-6Q05-DT-MY23; Version: 01; Dated: 17/05/2023 |
Protocol Number |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Dr Raji Patil |
| Designation |
Investigator |
| Affiliation |
MASCOT-SPINCONTROL India Pvt. Ltd. |
| Address |
Kohinoor Estate, 3rd Floor, Sun Mill Compound, Lower Parel West, Mumbai.
Mumbai
MAHARASHTRA
400013
India |
| Phone |
02243349191 |
| Fax |
|
| Email |
raji@mascotspincontrol.in |
|
Details of Contact Person
Scientific Query
|
| Name |
Dr Raji Patil |
| Designation |
Investigator |
| Affiliation |
MASCOT-SPINCONTROL India Pvt. Ltd. |
| Address |
Kohinoor Estate, 3rd Floor, Sun Mill Compound, Lower Parel West, Mumbai.
MAHARASHTRA
400013
India |
| Phone |
02243349191 |
| Fax |
|
| Email |
raji@mascotspincontrol.in |
|
Details of Contact Person
Public Query
|
| Name |
Dr Mohit Lalvani |
| Designation |
Study Director |
| Affiliation |
MASCOT-SPINCONTROL India Pvt. Ltd. |
| Address |
Kohinoor Estate, 3rd Floor, Sun Mill Compound, Lower Parel West, Mumbai.
Mumbai
MAHARASHTRA
400013
India |
| Phone |
02243349191 |
| Fax |
|
| Email |
mohit.CTRI@gmail.com |
|
|
Source of Monetary or Material Support
|
| MASCOT-SPINCONTROL India Pvt. Ltd., Kohinoor Estate, 3rd Floor, Sun Mill Compound, Lower Parel West, Mumbai. Mumbai (Suburban) MAHARASHTRA 400013 India |
|
|
Primary Sponsor
|
| Name |
DPKA Universal Consumer Ventures Private Limited |
| Address |
DPKA Universal Consumer Ventures Private Limited 3002, 30th Floor, Beau Monde, Tower B, Prabhadevi Road, Prabhadevi, Mumbai – 400025 |
| Type of Sponsor |
Other [FMCG] |
|
|
Details of Secondary Sponsor
|
| Name |
Address |
| NIL |
Not Applicable |
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Raji Patil |
Mascot Spincontrol India Pvt. Ltd. |
Kohinoor Estate, 3rd Floor, Sun Mill Compound, Lower Parel West, Mumbai.
Mumbai
MAHARASHTRA |
02243349191
raji@mascotspincontrol.in |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Ethos- An Institutional Ethics committee (Mumbai) |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Healthy Human Volunteers |
26 subjects with normal skin and 10 subjects with sensitive skin |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Intervention |
Gel Moisturizer |
0 microliters of product is dispensed on aluminium finn chambers and then be taped onto the back of subjects at T0 visit. This is a single application and the occluded patch is removed after 24 hours. |
| Comparator Agent |
Negative Control (0.9% Isotonic saline solution) |
40 microliters of 0.9% Isotonic saline solution is dispensed on aluminium finn chambers and then be taped onto the back of subjects at T1 visit. This is a single application and the occluded patch is removed after 24 hours. |
| Comparator Agent |
Positive Control (1% w/w SLS) |
40 microliters of 1% w/w Sodium Lauryl Sulphate is dispensed on aluminium finn chambers and then be taped onto the back of subjects at T1 visit. This is a single application and the occluded patch is removed after 24 hours. |
|
|
Inclusion Criteria
|
| Age From |
18.00 Year(s) |
| Age To |
65.00 Year(s) |
| Gender |
Both |
| Details |
1) Healthy Human Subjects
2) Skin should be healthy on the studied anatomic unit (free of eczema, wounds, inflammatory scar….).
3) Subjects willing to come for regular follow up and ready to follow instructions during the study period.
4)10 sensitive skin volunteers (declared by lactic acid stinging test)
|
|
| ExclusionCriteria |
| Details |
1 For female: Being pregnant or breastfeeding or having stopped to breastfeed in the past three months
2 Having refused to give his/her assent by not signing the consent form
3 Taking part in another study liable to interfere with this study
4 Being diabetic.
5 Being asthmatic.
6 Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, antihistamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol).
7 Having cutaneous hypersensitivity (except in the case of studies with evaluation of sensitive skin).
8 Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products.
9 Having undergone a surgery requiring a general anaesthesia of more than one hour in the past 6 months.
10 Having changed his/her cosmetic habits in the 14 days preceding the start of the study on the studied anatomic unit.
11 The day of the patch application: no cosmetic product must be used (test site clean with water only). Refusing to follow the restrictions below during the study: - For female: Do not become pregnant nor breastfeed. - Do not take part in another study liable to interfere with this study - Do not take medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, and antihistamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol). - Do not change his/her cosmetic habits apart from the particular conditions mentioned in the protocol, on the studied anatomic unit
12 Having eczema, psoriasis, lichen plan, vitiligo whatever the considered area
13 Having disorder of the healing (whatever the considered area) • Having a rhinitis, allergic conjunctivitis, or rhino sinusitis
14 Having an allergy to perfumes and/or conservatives in cosmetic products
15 Having an allergy to plaster
16 Having a food allergy
17 Having a cardiovascular pathology (taking a beta blocker treatment)
18 Having immunosuppressive drugs, such as cyclophosphamide, methotrexate, azathioprine, etc.
19 Taking a retinoid-based treatment by general or oral route
20 Taking specific treatment on the back.
21 Having taken an anti-histaminic treatment in the last 2 weeks preceding the start of the study
22 Having miliaria (prickly heat) on the back.
23 Presenting too many naevus on the back
24 Having high pilosity on the back.
25 Refusing to follow the restrictions below during the study: - During the first 24 hours (after patch application), neither cosmetic products nor water must be applied on the back. - Till the follow up period of until T8 days, only water is accepted from the first reading i.e., T2 days (24 hours after the patch removal). - Do not practice an intensive sport activity during the first 24 hours (until the removal of the patches) - Do not expose the back to the sun. |
|
|
Method of Generating Random Sequence
|
Not Applicable |
|
Method of Concealment
|
Not Applicable |
|
Blinding/Masking
|
Not Applicable |
|
Primary Outcome
|
| Outcome |
TimePoints |
| Dermatological safety / Irritation potential on skin |
Baseline,0 hrs,24 hrs & 7 days |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| Nil |
Not Applicable |
|
|
Target Sample Size
|
Total Sample Size="36"
Sample Size from India="36"
Final Enrollment numbers achieved (Total)= "25"
Final Enrollment numbers achieved (India)="25" |
|
Phase of Trial
|
N/A |
|
Date of First Enrollment (India)
|
16/06/2023 |
| Date of Study Completion (India) |
27/06/2023 |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Date Missing |
|
Estimated Duration of Trial
|
Years="0"
Months="0"
Days="8" |
Recruitment Status of Trial (Global)
Modification(s)
|
Not Applicable |
| Recruitment Status of Trial (India) |
Completed |
|
Publication Details
|
Nil |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
Single Application, occlusive, Closed Patch Test is conducted to measure the irritation potential of cosmetic products on the skin. Objective: The objective of this study is to evaluate the irritation potential on healthy human subjects of Skin Care Formulation. Duration of study: 8 days study Kinetics: T0 (Evaluation of test sites by Dermatologist, Patch application) T1(Patch removal, Evaluation of test sites by Dermatologist T2(Evaluation of test sites by Dermatologist and Subject post 24 hrs of patch removal), T8 (Evaluation of test sites by Dermat and Subject post 1 week of patch removal and tracking the positive cases) Population: 36 healthy subjects (18 males + 18 females) . 26 volunteers with normal skin and 10 volunteers with sensitive skin(declared by lactic acid stinging test) type. The test area is checked for erythema and oedema caused due to the products and compared with positive control. |